Business Wire

ADVA timing card brings precise synchronization to open compute servers

9.11.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today launched its OSA 5400 TimeCard™, enabling operators of data center network infrastructure and 5G open RAN architectures to achieve highly accurate and reliable distribution and synchronization of time. Built on the OSA 5400 SyncModule™, ADVA’s new PCIe card brings sophisticated timing capabilities to any open compute server, transforming it into a precise and stable PTP grandmaster, boundary clock, slave clock or NTP server. The OSA 5400 TimeCard™ is the market’s first solution developed to the framework of the Open Compute Project’s (OCP) Time Appliance Project (TAP) and enhanced with both PTP and NTP functions. With advanced synchronization capabilities, it solves a key challenge for network operators as they virtualize their infrastructure and replace purpose-built hardware with standard servers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005255/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s OSA 5400 TimeCard™ is the industry’s first solution developed to the framework of the Open Compute Project’s Time Appliance Project. (Photo: Business Wire)

“Timing in data centers and other open compute cases like 5G open RAN is becoming increasingly crucial as a growing number of applications require new levels of performance. But the sub-microsecond synchronization needed for efficient resource sharing is something that open compute servers often cannot provide. Open compute customers need a way to inject the most advanced synchronization capabilities into their white box hardware. That’s why we’ve engineered our OSA 5400 TimeCard™. It brings our experience in network and application synchronization to open compute servers as well as open RAN equipment, enabling a whole new group of customers to benefit from our unique expertise,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our feature-rich OSA 5400 TimeCard™ meets and goes beyond OCP-TAP specifications. For data centers, finance and 5G infrastructure, it’s the key to bringing packet time distribution to the edge and access network.”

Developed specifically to OCP-TAP specifications, ADVA’s new OSA 5400 TimeCard™ is enhanced with an integrated GNSS receiver, PTP, NTP, PTP assurance, GNSS assurance and mitigation engines, as well as full sync management functionality. Easily plugged into a free PCIe slot of a standard open compute server or PC, it delivers extremely robust and precise synchronization. It offers a wide range of oscillator options to cost-effectively meet different levels of holdover requirements. Unlike competing solutions, the OSA 5400 TimeCard™ is designed for simplicity and assured operations. Its powerful control interface provides comprehensive device information as well as data on the performance of the timing network. The OSA 5400 TimeCard™ provides transparent assurance and can be managed by ADVA’s Ensemble Sync Director. Comprehensive visibility of the timing infrastructure puts operational teams in complete control, even with no specialist expertise in network synchronization.

“In a wide range of industries, the need is now being recognized for highly precise and stable synchronization of time and frequency across packet networks. But the race to roll our cost-effective standard hardware and embrace the advantages of server virtualization often leaves a timing gap. As strict synchronization is now vital for more and more applications, operators urgently need an efficient way to bring tight timing to open compute servers. Our OSA 5400 TimeCard™ is the answer,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Our PCIe pluggable card will empower data center operators, enterprises, utilities, broadcast networks, financial networks and 5G mobile service providers to harness time-sensitive applications through reliable, scalable and high-accuracy timing.”

Further details on the OSA 5400 TimeCard™ are available in these slides: https://adva.li/osa-5400-timecard-slides.


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye